1. Pavlidis P, Bjarnason I. Aspirin induced adverse effects on the small and large intestine. Curr Pharm Des. 2015;21:5089–5093. doi:10.2174/1381612821666150915110058.
2. Endo H, Sakai E, Kato T, Umezawa S, Higurashi T, Ohkubo H, Nakajima A. Small bowel injury in low-dose aspirin users. J Gastroenterol. 2015;50:378–386. doi:10.1007/s00535-014-1028-x.
3. Smecuol E, Pinto Sanchez MI, Suarez A, Argonz JE, Sugai E, Vazquez H, Litwin N, Piazuelo E, Meddings JB, Bai JC, et al. Low-dose aspirin affects the small bowel mucosa: results of a pilot study with a multidimensional assessment. Clin Gastroenterol Hepatol. 2009;7:524–529. doi:10.1016/j.cgh.2008.12.019.
4. Ohira T, Iso H. Cardiovascular disease epidemiology in Asia. Circ J. 2013;77:1646–1652. doi:10.1253/circj.CJ- 13-0702.
5. Nier A, Brandt A, Conzelmann IB, Ozel Y, Bergheim I. Non-alcoholic fatty liver disease in overweight chil- dren: role of fructose intake and dietary pattern. Nutrients. 2018;10:1329. doi:10.3390/nu10091329.
6. Arslan N. Obesity, fatty liver disease and intestinal microbiota. World J Gastroenterol. 2014;20:16452–16463. doi:10.3748/wjg.v20.i44.16452.
7. Seki K, Kitade M, Nishimura N, Kaji K, Asada K, Namisaki T, Moriya K, Kawaratani H, Okura Y, Takaya H, et al. Oral administration of fructose exacer- bates liver fibrosis and hepatocarcinogenesis via increased intestinal permeability in a rat steatohepatitis model. Oncotarget. 2018;9:28638–28651. doi:10.18632/ oncotarget.25587.
8. Kinoshita Y, Ishimura N, Ishihara S. Advantages and dis- advantages of long-term proton pump inhibitor use. J Neurogastroenterol Motil. 2018;24:182–196. doi:10.5056/ jnm18001.
9. Wallace JL, Syer S, Denou E, de Palma G, Vong L, McKnight W, Jury J, Bolla M, Bercik P, Collins SM. Proton pump inhibitors exacerbate NSAID-induced small intestine injury by inducing dysbiosis. Gastroenterology. 2011;141:1314–1322. doi:10.1053/j. gastro.2011.06.075.
10. Suzuki T, Masui A, Nakamura J, Shiozawa H, Aoki J, Nakae H, Tsuda S, Imai J, Hideki O, Matsushima M, et al. Yogurt containing Lactobacillus gasseri mitigates aspirin-induced small bowel injuries: A prospective, randomized, double-blind, placebo-controlled trial. Digestion. 2017;95:49–54. doi:10.1159/000452361.
11. Endo H, Higurashi T, Hosono K, Sakai E, Sekino Y, Iida H, Sakamoto Y, Koide T, Takahashi H, Yoneda M, et al. Efficacy of Lactobacillus casei treatment on small bowel injury in chronic low-dose aspirin users: a pilot randomized controlled study. J Gastroenterol. 2011;46:894–905. doi:10.1007/s00535-011-0410-1.
12. Kawahara T, Makizaki Y, Oikawa Y, Tanaka Y, Maeda A, Shimakawa M, Komoto S, Moriguchi K, Ohno H, Taniguchi K. Oral administration of Bifidobacterium bifidum G9-1 alleviates rotavirus gas- troenteritis through regulation of intestinal homeosta- sis by inducing mucosal protective factors. PLoS One. 2017;12:e0173979. doi:10.1371/journal.pone.0173979.
13. Amagase K, Murakimi T, Imasato A, Takemoto S, Tanaka R, Kato S, Takeuchi K. Beneficial effect of probiotic preparations on loxoprofen-induced small intestinal lesions in rats. Jpn Pharmacol Ther. 2014;42:581–589.
14. Taupin D, Podolsky DK. Trefoil factors: initiators of mucosal healing. Nat Rev Mol Cell Biol. 2003;4:721–732. doi:10.1038/nrm1203.
15. Mashimo M, Wu DC, Podolsky DK, Fishman MC. Impaired defense of intestinal mucosa in mice lacking intestinal trefoil factor. Science. 1996;274:262–265. doi:10.1126/science.274.5285.262.
16. Ahrne S, Hagslatt ML. Effect of lactobacilli on para- cellular permeability in the gut. Nutrients. 2011;3:104–117. doi:10.3390/nu3010104.
17. Derrien M, Vaughan EE, Plugge CM, de Vos WM. Akkermansia muciniphila gen. nov., sp. nov., a human intestinal mucin-degrading bacterium. Int J Syst Evol Microbiol. 2004;54:1469–1476. doi:10.1099/ijs.0.02873-0.
18. Shattuck-Brandt RL, Varilek GW, Radhika A, Yang F, Washington MK, DuBois RN. Cyclooxygenase 2 expres- sion is increased in the stroma of colon carcinomas from IL-10(-/-) mice. Gastroenterology. 2000;118:337–345. doi:10.1016/S0016-5085(00)70216-2.
19. Kurokouch K, Kambe F, Yasukawa K, Izumi R, Ishiguro N, Iwata H, Seo H. TNF-alpha increases expression of IL-6 and ICAM-1 genes through activation of NF-kappaB in osteoblast-like ROS17/2.8 cells. J Bone Min Res. 1998;13:1290–1299. doi:10.1359/jbmr.1998.13.8.1290.
20. Yamamoto M, Yamazaki S, Uematsu S, Sato S, Hemmi H, Hoshino K, Kaisho T, Kuwata H, Tateuchi O, Takeshige K, et al. Regulation of Toll/IL-1-receptor-mediated gene expression by the inducible nuclear protein IkappaBzeta. Nature. 2004;430:218–222. doi:10.1038/nature02738.
21. Day RO, Graham GG. Non-steroidal anti-inflammatory drugs (NSAIDs). BMJ. 2013;346:f3195. doi:10.1136/bmj. f1164.
22. Watari I, Oka S, Tanaka S, Igawa A, Nakano M, Aoyama T, Yoshida S, Chayama K. Comparison of small-bowel mucosal injury between low-dose aspirin and non-aspirin non-steroidal anti-inflammatory drugs: a capsule endoscopy study. Digestion. 2014;89:225–231. doi:10.1159/000358287.
23. Nonoyama K, Nakagawa K, Amagase K, Takeuchi K, Nakamura M, Okabe S. New method of inducing intestinal lesions in rats by intraduodenal administra- tion of aspirin. J Gastroenterol Hepatol. 2010;25:S15–22. doi:10.1111/j.1440-1746.2010.06227.x.
24. Lai Y, Zhong W, Yu T, Xia XS, Li JY, Ouyang H, Shan TD, Yang HS, Chen QK. Rebamipide promotes the regenera- tion of aspirin-induced small-intestine mucosal injury through accumulation of β-Catenin. PLoS One. 2015;10: e0132031. doi:10.1371/journal.pone.0132031.
25. Arakawa T, Watanabe T, Tanigawa T, Tomonaga K, Otani K, Nadatani Y, Fujiwara Y. Small intestine injury caused by NSAIDs/aspirin: finding new from old. Curr Med Chem. 2012;19:77–81. doi:10.2174/0929867128034 14105.
26. Watanabe T, Higuchi K, Kobata A, Nishio H, Tanigawa T, Shiba M, Tominaga K, Fujiwara Y, Oshitani N, Asahara T, et al. Non-steroidal anti-inflammatory drug-induced small intestinal damage is Toll-like receptor 4 dependent. Gut. 2008;57:181–187. doi:10.1136/gut.2007.125963.
27. Hojo M, Asahara T, Nagahara A, Takeda T, Matsumoto K, Ueyama H, Matsumoto K, Asaoka D, Takahashi T, Nomoto K, et al. Gut microbiota composition before and after use of proton pump inhibitors. Dig Dis Sci. 2018;63:2940–2949. doi:10.1007/s10620-018-5122-4.
28. Shin CM, Kim N, Kim YS, Nam RH, Park JH, Lee DH, Seok YJ, Kim YR, Kim JH, Kim JM, et al. Impact of long-term proton pump inhibitor therapy on gut microbiota in F344 Rats: pilot study. Gut Liver. 2016;10:896–901. doi:10.5009/gnl15529.
29. Jackson MA, Goodrich JK, Maxan ME, Freedberg DE, Abrams JA, Poole AC, Sutter JL, Welter D, Ley RE, Bell JT, et al. Proton pump inhibitors alter the composition of the gut microbiota. Gut. 2016;65:749–756. doi:10.1136/gutjnl-2015-310861.
30. Imhann F, Bonder MJ, Vich Vila A, Fu J, Mujagic Z, Vork L, Tigchelaar EF, Jankipersadsing SA, Cenit MC, Harmsen HJ, et al. Proton pump inhibitors affect the gut microbiome. Gut. 2016;65:740–748. doi:10.1136/gutjnl- 2015-310376.
31. Gnauck A, Lentle RG, Kruger MC. The characteristics and function of bacterial lipopolysaccharides and their endotoxic potential in humans. Int Rev Immunol. 2016;35:189–218. doi:10.3109/08830185.2015.1087518.
32. Nygard G, Hudson M, Mazure G, Anthony A, Dhillon AP, Pounder RE, Wakefield AJ. Procoagulant and prothrom- botic responses of human endothelium to indomethacin and endotoxin in vitro. Relevance to non-steroidal anti- inflammatory drug enteropathy. Scand J Gastroenterol. 1995;30:25–32. doi:10.3109/00365529509093231.
33. Zhu W, Gregory JC, Org E, Buffa JA, Gupta N, Wang Z, Li L, Fu X, Wu Y, Mehrabian M, et al. Gut Microbial Metabolite TMAO Enhances Platelet Hyperreactivity and Thrombosis Risk. Cell. 2016;165:111–124. doi:10.1016/j.cell.2016.02.011.
34. Desai MS, Seekatz AM, Koropatkin NM, Kamada N, Hickey CA, Wolter M, Pudlo NA, Kitamoto S, Terrapon N, Muller A. A Dietary Fiber-Deprived Gut Microbiota Degrades the Colonic Mucus Barrier and Enhances Pathogen Susceptibility. Cell. 2016;167:1339–1353. doi:10.1016/j.cell.2016.10.043.
35. Sands SA, Tsau S, Yankee TM, Parker BL, Ericsson AC, LeVine SM. The effect of omeprazole on the develop- ment of experimental autoimmune encephalomyelitis in C57BL/6J and SJL/J mice. BMC Res Notes. 2014;7:605. doi:10.1186/1756-0500-7-605.
36. Mangin I, Dossou-Yovo F, Leveque C, Dessoy MV, Sawoo O, Suau A, Pochart P. Oral administration of viable Bifidobacterium pseudolongum strain Patronus modified colonic microbiota and increased mucus layer thickness in rat. FEMS Microbiol Ecol. 2018;94:10. doi:10.1093/femsec/ fiy177.
37. Plovier H, Everard A, Druart C, Depommier C, Van Hul M, Geurts L, Chilloux J, Ottman N, Duparc T, Lichtenstein L, et al. A purified membrane protein from Akkermansia muciniphila or the pasteurized bac- terium improves metabolism in obese and diabetic mice. Nat Med. 2017;23:107–113. doi:10.1038/nm.4236.
38. Derrien M, Belzer C, de Vos WM. Akkermansia mucini- phila and its role in regulating host functions. Microb Pathog. 2017;106:171–181. doi:10.1016/j.micpath.2016.02.005.
39. Hänninen A, Toivonen R, Pöysti S, Belzer C, Plovier H, Ouwerkerk JP, Emani R, Cani PD, De Vos WM. Akkermansia muciniphila induces gut microbiota remo- delling and controls islet autoimmunity in NOD mice. Gut. 2018;67:1445–1453. doi:10.1136/gutjnl-2017-314508.
40. Anna E, Andre S, Malin EVJ, Jenny KG, Gunnar CH. Studies of mucus in mouse stomach, small intestine, and colon. I. Gastrointestinal mucus layers have different properties depending on location as well as over the Peyer’s patches. Am J Physiol Gastrointest Liver Physiol. 2013;305:G341–G347. doi:10.1152/ajpgi.00046.2013.
41. Everard A, Aron-Wisnewsky J, Sokolovska N, Prifti E, Verger EO, Kayser BD, Levenez F, Chilloux J, Hoyles L, Dumas ME, et al. Akkermansia muciniphila and improved metabolic health during a dietary intervention in obesity: relationship with gut microbiome richness and ecology. Gut. 2016;65:426–436. doi:10.1136/gutjnl-2014-308778.
42. Aamann L, Vestergaard EM, Grønbæk H. Trefoil factors in inflammatory bowel disease. World J Gastroenterol. 2014;20:3223–3230. doi:10.3748/wjg.v20.i12.3223.
43. Fornai M, Antonioli L, Colucci R, Pellegrini C, Giustarini G, Testai L, Martelli A, Matarangasi A, Natale G, Calderone V, et al. NSAID-Induced Enteropathy: Are the Currently Available Selective COX-2 Inhibitors All the Same? J Pharmacol Exp Ther. 2014;348:86–95. doi:10.1124/jpet.113.207118.
44. Tanaka A, Hase S, Miyazawa T, Ohno R, Takeuchi K. Role of cyclooxygenase (COX)-1 and COX-2 inhibition in non- steroidal anti-inflammatory drug-induced intestinal damage in rats: relation to various pathogenic events. J Pharmacol Exp Ther. 2002;303:1248–1254. doi:10.1124/ jpet.102.041715.
45. Smelt MJ, de Haan BJ, Bron PA, van Swam I, Meijerink M, Wells JM, Kleerebezem M, Faas MM, de Vos P. The impact of Lactobacillus plantarum WCFS1 teichoic acid D-Alanylation on the generation of effector and regulatory T-cells in healthy mice. PLoS One. 2013;8:e63099. doi:10.1371/journal.pone.0063099.
46. Macho FE, Valenti V, Rockel C, Hermann C, Pot B, Boneca IG, Grangette C. Anti-inflammatory capacity of selected lactobacilli in experimental colitis is driven by NOD2-mediated recognition of a specific peptidoglycan- derived muropeptide. Gut. 2011;60:1050–1059. doi:10.1136/gut.2010.232918.
47. Smith PM, Howitt MR, Panikov N, Michaud M, Gallini CA, Bohlooly YM, Glickman JN, Garrett WS. The microbial metabolites, short-chain fatty acids, reg- ulate colonic Treg cell homeostasis. Science. 2013;341:569–573. doi:10.1126/science.1241165.
48. Fukuda S, Toh H, Hase K, Oshima K, Nakanishi Y, Yoshimura K, Tobe T, Clarke JM, Topping DL, Suzuki T, et al. Bifidobacteria can protect from enter- opathogenic infection through production of acetate. Nature. 2011;469:543–547. doi:10.1038/nature09646.
49. Liu Y, Alookaran JJ, Rhoads JM. Probiotics in auto- immune and inflammatory disorders. Nutrient. 2018;10:1537. doi:10.3390/nu10101537.
50. Li MO, Flavell RA. TGF-β: A master of all T cell trades. Cell. 2008;134:392–404. doi:10.1016/j.cell.2008.07.025.
51. Makizaki Y, Maeda A, Oikawa Y, Tamura S, Tanaka Y, Nakajima S, Yamamura H. Alleviation of low-fiber diet-induced constipation by probiotic Bifidobacterium bifidum G9-1 is based on correction of gut microbiota dysbiosis. Biosci Microbiota Food Health. 2019;38:49–53. doi:10.12938/bmfh.18-020.
52. Rivière A, Selak M, Lantin D, Leroy F, De Vuyst L. Bifidobacteria and Butyrate-Producing Colon Bacteria: Importance and Strategies for Their Stimulation in the Human Gut. Front Microbiol. 2016;7:979. doi:10.3389/ fmicb.2016.00979.
53. Chiu CJ, McArdle AH, Brown R, Scott HJ, Gurd FN. Intestinal mucosal lesion in low-flow states. I. A morphological, hemodynamic and metabolic reap- praisal. Arch Surg. 1970;101:478–483. doi:10.1001/ archsurg.1970.01340280030009.
54. Schindelin J, Arganda-Carreras I, Frise E, Kaynig V, Longair M, Pietzsch S, Preibisch S, Rueden C, Saalfeld S, Schmid B, et al. Fiji: an open-source plat- form for biological-image analysis. Nat Methods. 2012;9:676–682. doi:10.1038/nmeth.2019.
55. Mizuno M, Noto D, Kaga N, Chiba A, Miyake S. The dual role of short fatty acid chains in the pathogenesis of autoimmune disease models. PLoS One. 2017;12: e0173032. doi:10.1371/journal.pone.0173032.
56. Lefrançois L, Lycke N. Isolation of mouse small intest- inal intraepithelial lymphocytes, Peyer’s patch, and lamina propria cells. Curr Protoc Immunol. 2001; Chapter 3:Unit 3.19.
57. Matsuki T, Watanabe K, Fujimoto J, Takada T, Tanaka R. Use of 16S rRNA gene-targeted group-specific primers for real-time PCR analysis of predominant bacteria in human feces. Appl Environ Microbiol. 2004;70:7220–7228. doi:10.1128/AEM.70.12.7220-7228.2004.
58. Fadrosh DW, Ma B, Gajer P, Sengamalay N, Ott S, Brotman RM, Ravel L. An improved dual-indexing approach for multiplexed 16S rRNA gene sequencing on the Illumina MiSeq platform. Microbiome. 2014;2:6. doi:10.1186/2049-2618-2-6.
59. Caporaso JG, Kuczynski J, Stombaugh J, Bittinger K, Bushman FD, Costello EK, Fierer N, Pena AG, Goodrich JK, Gordon JI, et al. QIIME allows analysis of high-throughput community sequencing data. Nat Methods. 2010;27:335–336. doi:10.1038/nmeth.f.303.
60. Fukui H, Oshima T, Tanaka Y, Oikawa Y, Makizaki Y, Ohno H, Tomita T, Watari J, Miwa H. Effect of pro- biotic Bifidobacterium bifidum G9-1 on the relation- ship between gut microbiota profile and stress sensitivity in maternally separated rats. Sci Rep. 2018;8:12384. doi:10.1038/s41598-018-30943-3.
61. Kim SW, Suda W, Kim S, Oshima K, Fukuda S, Ohno H, Morita H, Hattori M. Robustness of gut microbiota of healthy adults in response to probiotic intervention revealed by high-throughput pyrosequencing. DNA Res. 2013;20:241–253. doi:10.1093/dnares/dst006.
62. Lozupone C, Knight R. UniFrac: a new phylogenetic method for comparing microbial communities. Appl Environ Microbiol. 2005;71:8228–8235. doi:10.1128/ AEM.71.12.8228-8235.2005.
63. Kanda Y. Investigation of the freely available easy-to- use software ‘EZR’ for medical statistics. Bone Marrow Transplant. 2013;48:452–458. doi:10.1038/ bmt.2012.244.